 price
teach french perkin
thesi updat perkin continu transform higher
growth asset perkin way small increment dx deal
 acquir cisbio french reagents/consum provid
high-throughput drug screen forward ebitda
estim seem quit fair manag expect acceler growth
msd hsd deliv dd year four outsid
 firework manag plenti mix demand
trend within da still deliv solid core growth
overal busi whatev perkin diagnost side
seem work overal busi attract
fundament perspect acceler core growth improv
margin ep grow mid-teen plenti balanc sheet
capac addit capit deploy look
valuat perkin trade pe ev/ebitda wow
ye tool expens perkin trade premium
in-lin rob team done great job
busi old perkin need get
comfort emerg busi like euroimmun us
vanadi tulip expand emerg market mention
da still margin profil peer take factor
account scratch head valuat forc wait
better entri point would expect entri point
tomorrow stock like modestli beat thu
reiter rate
rais revenu bn vs bn prior
mm cisbio
share touch mm
rais ep vs prior
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
pick remain recognit delay deferr
biopharma continu grow hsd
 goe back posit order push
appli back msd
europ lsd
america hsd
 industrial/appli weak
biopharma hsd
appli lsd would msd ex-deferr government shutdown
cannabi lighter mm run-rat comfort order rate convert
food lighter region time china converg government food lab privat lab convert intern
environment custom
 lsd would flat ex-derr government shutdown
da driver
repro hsd genom test tract doubl rev
appli genom hsd autom sampl answer
euroimmun mid-teen
biopharma hsd discoveri portfolio high content screen vivo imag
expect vanadi instal end year
paid mm cisbio
bp omx driven
growth get hsd
revenu mm oper margin
euroimmun favor mix
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
laboratori corp america
articl articl
time dissemin april
analyst luke sergott jon bristow ross muken primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research report
